Sopharma Trading AD (XBUL:SFT) Piotroski F-Score: 6 (As of Jul. 02, 2026) — 20% Above Median


XBUL:SFT Sopharma Trading AD XBUL:SFT
82 GF Score
Price €2.90
GF Value €7.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD Piotroski F-Score?

Sopharma Trading AD XBUL:SFT -3.33% 82 Piotroski F-Score is 6 as of Jul. 02, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates XBUL:SFT with a GF Score™ of 82/100 and a GF Value™ of €7.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 112 Medical Distribution companies, Sopharma Trading AD ranks better than 76.79% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sopharma Trading AD has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sopharma Trading AD's Piotroski F-Score or its related term are showing as below:

XBUL:SFT' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Sopharma Trading AD was 9. The lowest was 3. And the median was 5.

Sopharma Trading AD  (XBUL:SFT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sopharma Trading AD Piotroski F-Score Related Terms


Sopharma Trading AD Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD Piotroski F-Score Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 9.00 8.00 6.00

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 5.00 6.00 6.00

XBUL:SFT vs MCK, CAH, COR: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Sopharma Trading AD's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma Trading AD Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sopharma Trading AD's Piotroski F-Score falls into.


XBUL:SFT
82GF Score
Sopharma Trading AD XBUL:SFT
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 9.143 + 6.319 + 1.974 + 8.367 = €26 Mil.
Cash Flow from Operations was -19.419 + 5.727 + 21.286 + 8.259 = €16 Mil.
Revenue was 285.559 + 284.744 + 304.694 + 303.303 = €1,178 Mil.
Gross Profit was 39.442 + 36.728 + 37.378 + 39.979 = €154 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(448.191 + 459.21 + 476.211 + 477.684 + 484.036) / 5 = €469.0664 Mil.
Total Assets at the begining of this year (Mar25) was €448 Mil.
Long-Term Debt & Capital Lease Obligation was €58 Mil.
Total Current Assets was €370 Mil.
Total Current Liabilities was €296 Mil.
Net Income was 5.411 + 4.035 + 4.205 + 12.142 = €26 Mil.

Revenue was 227.31 + 248.802 + 275.836 + 286.476 = €1,038 Mil.
Gross Profit was 27.757 + 30.795 + 35.469 + 39.988 = €134 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(357.916 + 364.739 + 405.84 + 408.842 + 448.191) / 5 = €397.1056 Mil.
Total Assets at the begining of last year (Mar24) was €358 Mil.
Long-Term Debt & Capital Lease Obligation was €61 Mil.
Total Current Assets was €342 Mil.
Total Current Liabilities was €283 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sopharma Trading AD's current Net Income (TTM) was 26. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sopharma Trading AD's current Cash Flow from Operations (TTM) was 16. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=25.803/448.191
=0.05757144

ROA (Last Year)=Net Income/Total Assets (Mar24)
=25.793/357.916
=0.07206439

Sopharma Trading AD's return on assets of this year was 0.05757144. Sopharma Trading AD's return on assets of last year was 0.07206439. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sopharma Trading AD's current Net Income (TTM) was 26. Sopharma Trading AD's current Cash Flow from Operations (TTM) was 16. ==> 16 <= 26 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=58.241/469.0664
=0.12416366

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=61.197/397.1056
=0.15410762

Sopharma Trading AD's gearing of this year was 0.12416366. Sopharma Trading AD's gearing of last year was 0.15410762. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=370.144/295.974
=1.25059634

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=341.774/282.642
=1.20921165

Sopharma Trading AD's current ratio of this year was 1.25059634. Sopharma Trading AD's current ratio of last year was 1.20921165. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sopharma Trading AD's number of shares in issue this year was 34.187. Sopharma Trading AD's number of shares in issue last year was 34.231. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=153.527/1178.3
=0.13029534

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=134.009/1038.424
=0.12905037

Sopharma Trading AD's gross margin of this year was 0.13029534. Sopharma Trading AD's gross margin of last year was 0.12905037. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1178.3/448.191
=2.62901308

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1038.424/357.916
=2.90130645

Sopharma Trading AD's asset turnover of this year was 2.62901308. Sopharma Trading AD's asset turnover of last year was 2.90130645. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sopharma Trading AD has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Sopharma Trading AD (XBUL:SFT) has a Piotroski F-Score of 6 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sopharma Trading AD and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Sopharma Trading AD's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Sopharma Trading AD ranks #26 out of 112 companies in the Medical Distribution industry, placing it in the top 23.2%.
Is Sopharma Trading AD's Piotroski F-Score too high?
Sopharma Trading AD's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Sopharma Trading AD's value of 6 is 20% above this industry median. Based on the distribution chart, Sopharma Trading AD ranks #26 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Piotroski F-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #26 out of 112 companies for Piotroski F-Score. This places Sopharma Trading AD in the top 23% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sopharma Trading AD's value of 6 is 20% above this benchmark. Historically, Sopharma Trading AD's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Sopharma Trading AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.62, compared to a current price of €2.90 — trading 61.9% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Distribution industry median of 5.00. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Piotroski F-Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €2.90 is trading 61.9% below its estimated GF Value™ of €7.62. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: €7.62 vs. price of €2.90 (61.9% below fair value)
  • GF Score™: 82/100 with 2 warning signs
  • Industry Position: 20% above the Medical Distribution median (#26 of 112)

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score

Get the complete analysis for XBUL:SFT

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€7.62
GF Value